Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Citations
1,530 citations
Cites background or methods from "Dabrafenib and trametinib versus da..."
...as well as stratification and analysis, are often based on the presence/absence of CNS disease.(6-20,73,74) Therefore, this additional level of granularity in the M category “maps” bet-...
[...]
...Instead, the legacy seventh edition AJCC stage IV International Melanoma Database was used for the eighth edition as the primary data source (and no new analyses were conducted), supplemented by published contemporary clinical trial data.(6-20) In the eighth edition, M-category definitions were clarified and refined, and a new category for patients with central nervous system (CNS) metastases was added (M1d)....
[...]
...Instead, the legacy seventh edition AJCC stage IV International Melanoma Database containing details of approximately 10,000 patients who presented with or developed stage IV disease was used as the primary data source for the eighth edition and was supplemented by data from published contemporary clinical trials.(6-20)...
[...]
...More recently, based upon improved knowledge of both the molecular pathogenesis of melanoma and cancer immunology, there has been a revolution in the treatment of patients with advanced stage and unresectable melanoma.(6-20) This has already resulted in major improvements in patient outcomes....
[...]
1,017 citations
943 citations
885 citations
795 citations
References
20,760 citations
13,081 citations
4,612 citations
4,602 citations
2,962 citations